Department of Pharmacology, Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195-7280, USA.
Glia. 2010 Jul;58(9):1017-30. doi: 10.1002/glia.20983.
CB1 and CB2 receptors are activated by a plethora of cannabinoid compounds, be they endogenously-produced, plant-derived or synthetic. These receptors are expressed by microglia, astrocytes and astrocytomas, and their activation regulates these cells' differentiation, functions and viability. Recent studies show that glial cells also express cannabinoid-like receptors, and that their activation regulates different cell functions, but also control cell viability. This review summarizes this evidence, and discusses how selective compounds targeting cannabinoid-like receptors constitute promising therapeutics to manage neuroinflammation and eradicate malignant astrocytomas. Importantly, the selective targeting of cannabinoid-like receptors should provide therapeutic relieve without inducing the typical psychotropic effects and possible addictive properties associated with the use of Delta9-tetrahydrocannabinol, the main psychotropic ingredient produced by the plant Cannabis sativa.
CB1 和 CB2 受体可被大量的大麻素化合物激活，这些化合物可以是内源性的、植物源性的或合成的。这些受体由小胶质细胞、星形胶质细胞和星形细胞瘤表达，它们的激活调节这些细胞的分化、功能和存活。最近的研究表明，神经胶质细胞也表达大麻素样受体，其激活调节不同的细胞功能，但也控制细胞活力。这篇综述总结了这方面的证据，并讨论了针对大麻素样受体的选择性化合物如何构成管理神经炎症和根除恶性星形细胞瘤的有希望的治疗方法。重要的是，选择性地针对大麻素样受体应该可以提供治疗缓解，而不会引起与使用大麻植物中主要精神活性成分 Delta9-四氢大麻酚相关的典型精神作用和可能的成瘾性。
